Company Overview and News

 
Pacifico Minerals up 36% after being granted exploration licence prospective for zinc-lead

2018-05-16 proactiveinvestors.com.au
Pacifico Minerals Ltd (ASX:PMY) jumped 36% on strong volume of 31 million on news of being granted an exploration licence in the Northern Territory prospective for zinc-lead.

 
Pacifico Minerals a leading ASX gainer after executing drilling contract at copper prospect

2018-03-02 proactiveinvestors.com.au
Pacifico Minerals Ltd (ASX:PMY) is a leading ASX gainer on news of executing a drilling contract for its Borroloola West base metals project in the Northern Territory.

 
Pacifico Minerals in an ASX trading halt

2017-03-27 proactiveinvestors.com.au
Pacifico Minerals (ASX:PMY) has been granted a trading halt by the ASX, pending details of a capital raising.

 
Pacifico Minerals extents drilling program at Borroloola West

2016-10-18 proactiveinvestors.com.au
The drilling was done at the Four Mile, Coppermine Creek, Johnstons and Mariner prospects and the company will now move onto the Berjaya tenement. Importantly, indications of copper, lead and zinc mineralisation were observed in several holes. Assay results are expected in early November. Pacifico holds 51% and is the operator of the Borroloola West project alongside Sandfire Resources NL (ASX:SFR).

 
Pacifico Minerals Ltd starts drilling for zinc-copper with Sandfire Resources

2016-06-30 proactiveinvestors.com.au
Pacifico Minerals Ltd (ASX:PMY) will start a drilling program for zinc and copper at the Borroloola West project in the Northern Territory along with JV partner Sandfire Resources NL (ASX:SFR). It is worth noting that the Borroloola tenements are just 15 kilometres east of the McArthur River mining area, one of the world’s largest zinc, lead and silver mines. Pacifico had completed exploration expenditure of $1.

 
Half Year Accounts

2016-03-09 asx.com.au

 
Cancellation of Options

2016-03-01 asx.com.au

 
Cancellation of Options

2016-01-27 asx.com.au

 
Pacifico Minerals to drill promising Colombian gold targets

2016-01-26 proactiveinvestors.com.au
An imminent diamond core drilling program by Pacifico Minerals (ASX:PMY) is targeting three high-interest zones along a mineralised faulted contact at the Berrio gold project in Colombia . The 2000-metrte campaign us set to begin later this month and continue into early March, offering the company near-term newsflow as it continues to enhance a project only 35 kilometres by navigable river to the Caribbean Sea with existing infrastructure including hydro power, sealed roads, water supply and telecommunications coverage.

 
Pacifico to drill Berrio gold

2016-01-25 news.smh.com.au
Pacifico Minerals will commence a diamond drilling program at the Berrio gold project, Antioquia, Colombia, targeting three zones of high interest.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

20h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

20h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...